Business Context and Reporting Period
This Form 8-K reports on the reconvened 2022 Annual Meeting of Stockholders for Vistagen Therapeutics, Inc., held on October 28, 2022. The meeting was called to vote on specific proposals that were not resolved during the initial meeting on October 14, 2022.
Key Financial Metrics
This filing is a current report regarding corporate governance and stockholder votes. It does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data.
Material Changes and Voting Results
Stockholders voted on two proposals at the reconvened meeting. The total number of outstanding shares entitled to vote was 206,836,945.
- Proposal No. 5 (Approved): Stockholders approved discretionary authorization for the Board to implement a reverse stock split of the Company's common stock at a ratio between 1-for-2 and 1-for-30.
- For: 104,229,120 votes
- Against: 25,372,666 votes
- Abstain: 4,016,453 votes
- Proposal No. 6 (Not Approved): Stockholders did not approve an amendment to the Company's Bylaws that would have allowed the Board to determine the number of directors in its sole discretion.
- For: 65,592,186 votes
- Against: 24,302,176 votes
- Abstain: 3,454,611 votes
Guidance, Outlook, and Risks
The filing does not provide financial guidance, management commentary on future operations, or specific risk factors beyond the context of the voting proposals. The approval of the reverse stock split authorization allows the Board to effect the split at any time prior to October 14, 2023, if deemed necessary.
Key Facts for Investor Verification
- Verify the exact reverse stock split ratio and implementation date, as the Board now has discretion to act between 1-for-2 and 1-for-30.
- Confirm the current number of directors on the Board, as the proposal to allow the Board to set this number unilaterally was rejected.
- Review the Company's Proxy Statement filed on August 31, 2022, for detailed background on the proposals.
- Check subsequent filings for the actual execution of the reverse stock split, if the Board chooses to proceed.